Johnson & Johnson executives decided to phase out a replacement hip joint and sell its remaining inventory to be surgically implanted in patients just weeks after the company got a letter from the Food and Drug Administration about serious safety concerns with the devices.
The Times cites documents it attained under the Freedom of Information Act.
A report in the New York Times says that after receiving the letter, company executives waited a year to take the DePuy hip implants off the ...
continue reading...